Table 3.
Changes in aberrant behaviors of children assessed with the ABC-J
| Subscales | Visitsa | Changesb | Wilcoxon’s signed rank sum testc |
|||
|---|---|---|---|---|---|---|
| n | Q1 | Median | Q3 | P value | ||
| I (irritability) | 2 | – | – | – | – | – |
| 5 | 99 | −4 | 0.0 | 2 | 0.1197 | |
| 9 | 97 | −5 | −1.0 | 2 | 0.0094 | |
| II (lethargy) | 2 | – | – | – | – | – |
| 5 | 99 | −3 | 0.0 | 3 | 0.5533 | |
| 9 | 97 | −4 | −1.0 | 3 | 0.1267 | |
| III (stereotypic behavior) | 2 | – | – | – | – | – |
| 5 | 99 | −2 | 0.0 | 0 | 0.0322 | |
| 9 | 97 | −2 | 0.0 | 1 | 0.1035 | |
| IV (hyperactivity) | 2 | – | – | – | – | – |
| 5 | 99 | −5 | 0.0 | 4 | 0.5504 | |
| 9 | 97 | −6 | −1.0 | 2 | 0.0025 | |
| V (inappropriate speech) | 2 | – | – | – | – | – |
| 5 | 99 | −1 | 0.0 | 1 | 0.3078 | |
| 9 | 97 | −2 | 0.0 | 1 | 0.0125 | |
a: visit 2 = end of the screening phase; visit 5 = week 10 of the medication phase II; visit 9 = week 26 of the medication phase II
b: Change = (measured value at each visit) - (measured value at visit 2)
c: Comparison against visit 2
ABC-J Aberrant Behavior Check List-Japanese version